Efficacy and safety of first-line (1L) nivolumab plus relatlimab (NIVO + RELA) versus NIVO plus ipilimumab (NIVO + IPI) in advanced melanoma: An indirect treatment comparison (ITC) using patient-level data (PLD).

Authors :: Schadendorf, Dirk
Tawbi, Hussein A.
Lipson, Evan J.
Hodi, F. Stephen
Ascierto, Paolo Antonio
Larkin, James
Lao, Christopher D.
Grob, Jean-Jacques
Ejzykowicz, Flavia
Moshyk, Andriy
Horton, Viviana Garcia
Zhou, Jenny
Xin, Yiqiao
Palaia, Jennell
McDonald, Laura
Keidel, Sarah
Salvatore, Anthony
Sakkal, Leon A.
Long, Georgina V.
Source :: Journal of Clinical Oncology; 2023 Supplement 16, Vol. 41, p9552-9552, 1p
Publication Year :: 2023

Full Text Access

Tools